Vericel (VCEL) versus Neuralstem (CUR) Head-To-Head Survey

Share on StockTwits

Vericel (NASDAQ: CUR) and Neuralstem (NASDAQ:CUR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, earnings, profitability, risk and dividends.

Analyst Recommendations

This is a summary of recent ratings and target prices for Vericel and Neuralstem, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vericel 0 0 5 0 3.00
Neuralstem 0 0 0 0 N/A

Vericel presently has a consensus price target of $15.00, indicating a potential upside of 14.94%. Neuralstem has a consensus price target of $1.91, indicating a potential upside of 66.09%. Given Neuralstem’s higher possible upside, analysts plainly believe Neuralstem is more favorable than Vericel.

Earnings & Valuation

This table compares Vericel and Neuralstem’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vericel $63.92 million 8.72 -$17.28 million ($0.50) -26.10
Neuralstem $260,000.00 67.05 -$15.66 million N/A N/A

Neuralstem has lower revenue, but higher earnings than Vericel.

Insider & Institutional Ownership

76.5% of Vericel shares are held by institutional investors. Comparatively, 7.4% of Neuralstem shares are held by institutional investors. 3.3% of Vericel shares are held by company insiders. Comparatively, 30.1% of Neuralstem shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Vericel and Neuralstem’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Vericel -23.35% -37.86% -21.19%
Neuralstem -1,401.80% -75.90% -48.98%

Volatility & Risk

Vericel has a beta of 2.99, meaning that its stock price is 199% more volatile than the S&P 500. Comparatively, Neuralstem has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500.

Summary

Vericel beats Neuralstem on 7 of the 11 factors compared between the two stocks.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Carticel, an autologous chondrocyte implant for the repair of symptomatic cartilage defects of the femoral condyle caused by acute or repetitive trauma in patients that have inadequate response to a prior arthroscopic or other surgical repair procedure. The company also markets Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. In addition, it develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.

About Neuralstem

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply